Ogiso et al. [12] showed that ezetimibe combined with pitavastatin for the treatment of coronary heart disease could effectively improve the efficacy, improve lipids and carotid plaque, reduce hs-CRP and CX3CR-1 expression, and improve endothelial cell function in patients, resulting in clinical benefits for patients with coronary heart pain, consistent with the findings of this paper. This evidence concerns the gene CRP and benign neoplasm.